I. Rita Jain's most recent trade in AnaptysBio Inc was a trade of 16,510 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 7, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
AnaptysBio Inc | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
AnaptysBio Inc | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
AnaptysBio Inc | Rita I. Jain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 4,534 | 4,534 (0%) | 0% | 0 | Common Stock | |
AnaptysBio Inc | Rita I. Jain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,234 | 0 | - | - | Restricted Stock Unit | |
AnaptysBio Inc | Rita I. Jain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 1,300 | 0 | - | - | Restricted Stock Unit | |
Celldex Therapeutics Inc. | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 16,500 | 16,500 | - | - | Non-Qualified Stock Option (right to buy) | |
AnaptysBio Inc | Jain Rita I. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
AnaptysBio Inc | I. Rita Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
AnaptysBio Inc | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
AnaptysBio Inc | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 8,015 | 8,015 | - | - | Stock Option (right to buy) | |
AnaptysBio Inc | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
AnaptysBio Inc | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,234 | 3,234 | - | - | Restricted Stock Unit | |
Celldex Therapeutics Inc. | Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 17,100 | 17,100 | - | - | Non-Qualified Stock Option (right to buy) | |
Immunovant Inc | Rita I. Jain | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 342,300 | 342,300 | - | - | Stock Option (right to buy) | |
Immunovant Inc | Rita I. Jain | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 97,600 | 117,600 (0%) | 0% | 0 | Common Stock | |
Immunovant Inc | Rita I. Jain | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 11,765 | 129,365 (0%) | 0% | 0 | Common Stock | |
Immunovant Inc | Rita I. Jain | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 220,000 | 220,000 | - | - | Stock Option (right to buy) | |
Immunovant Inc | Rita I. Jain | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2021 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock |